Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels
- PMID:10632247
Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels
Abstract
Objectives: To determine the efficacy of nicotine patch therapy in adolescents who want to stop smoking and to assess biochemical markers of smoking and nicotine intake.
Design: Nonrandomized, open-label trial using a 15 mg/16 h patch.
Setting: Two midwestern cities.
Subjects: One hundred one adolescents aged 13 through 17 years smoking at least 10 cigarettes per day (cpd).
Intervention: Six weeks of nicotine patch therapy and follow-up visits at 12 weeks and 6 months.
Main outcome measures: Self-reported smoking abstinence verified by expired-air carbon monoxide (CO) level of no more than 8 ppm, nicotine withdrawal symptoms, and plasma cotinine level.
Results: Forty-one participants were female (mean [+/- SD] age, 16.5 [+/- 1.1] years). Median baseline smoking rate was 20.0 cpd (range, 10-40 cpd). Biochemically confirmed point prevalence smoking abstinence was 10.9% (11/101) at 6 weeks and 5.0% (5/101) at 6 months. The mean (+/- SD) plasma cotinine level at baseline was 1510.9 +/- 732.7 nmol/L; for nonsmoking subjects at weeks 3 and 6, 607.8 +/- 386.2 and 710.0 +/- 772.5 nmol/L, respectively. Plasma cotinine levels were correlated with CO levels at baseline (r = 0.27; P = .006), week 3 (r = 0.34; P = .004), and week 6 (r = 0.26; P = .03) and with mean cigarettes smoked per day during weeks 3 (r = 0.24; P = .04) and 6 (r = 0.30; P = .02). Mean smoking rates decreased significantly during the study, an effect that lessened at 12 weeks and 6 months.
Conclusions: Nicotine patch therapy plus minimal behavioral intervention does not appear to be effective for treatment of adolescent smokers. Plasma cotinine and CO levels appear to be valid measures of smoking rates during the cessation process, but not at baseline. Smoking rates were reduced throughout the study. Additional pharmacological and behavioral treatments should be considered in adolescent smokers.
Comment in
- Promoting adolescent smoking cessation is worth the effort.McFee RB, Boykan R, Lasner H, Mazure B.McFee RB, et al.Arch Pediatr Adolesc Med. 2001 Mar;155(3):419-20.Arch Pediatr Adolesc Med. 2001.PMID:11231818No abstract available.
Similar articles
- Nicotine patch therapy in adolescent smokers.Smith TA, House RF Jr, Croghan IT, Gauvin TR, Colligan RC, Offord KP, Gomez-Dahl LC, Hurt RD.Smith TA, et al.Pediatrics. 1996 Oct;98(4 Pt 1):659-67.Pediatrics. 1996.PMID:8885942Clinical Trial.
- Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction.Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, Schroeder JR.Moolchan ET, et al.Pediatrics. 2005 Apr;115(4):e407-14. doi: 10.1542/peds.2004-1894.Pediatrics. 2005.PMID:15805342Clinical Trial.
- Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial.Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT.Schuurmans MM, et al.Addiction. 2004 May;99(5):634-40. doi: 10.1111/j.1360-0443.2004.00711.x.Addiction. 2004.PMID:15078238Clinical Trial.
- A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.Robles GI, Singh-Franco D, Ghin HL.Robles GI, et al.Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010.Clin Ther. 2008.PMID:18555928Review.
- [Smoking cessation with the nicotine patch].Batra A, Buchkremer G.Batra A, et al.Z Arztl Fortbild (Jena). 1995 Oct;89(5):505-9.Z Arztl Fortbild (Jena). 1995.PMID:8578778Review.German.
Cited by
- Teen smoking cessation.Mermelstein R.Mermelstein R.Tob Control. 2003 Jun;12 Suppl 1(Suppl 1):i25-34. doi: 10.1136/tc.12.suppl_1.i25.Tob Control. 2003.PMID:12773783Free PMC article.Review.
- Pediatricians' use of the 5 A's and nicotine replacement therapy with adolescent smokers.Price JH, Jordan TR, Dake JA.Price JH, et al.J Community Health. 2007 Apr;32(2):85-101. doi: 10.1007/s10900-006-9035-3.J Community Health. 2007.PMID:17571523
- Nicotine administration in adolescence reprograms the subsequent response to nicotine treatment and withdrawal in adulthood: sex-selective effects on cerebrocortical serotonergic function.Slotkin TA, Card J, Seidler FJ.Slotkin TA, et al.Brain Res Bull. 2014 Mar;102:1-8. doi: 10.1016/j.brainresbull.2014.01.004. Epub 2014 Jan 30.Brain Res Bull. 2014.PMID:24487013Free PMC article.
- Cholinergic transmission during nicotine withdrawal is influenced by age and pre-exposure to nicotine: implications for teenage smoking.Carcoba LM, Orfila JE, Natividad LA, Torres OV, Pipkin JA, Ferree PL, Castañeda E, Moss DE, O'Dell LE.Carcoba LM, et al.Dev Neurosci. 2014;36(3-4):347-55. doi: 10.1159/000360133. Epub 2014 May 15.Dev Neurosci. 2014.PMID:24854235Free PMC article.
- Tailoring nicotine replacement therapy: rationale and potential approaches.McClure JB, Swan GE.McClure JB, et al.CNS Drugs. 2006;20(4):281-91. doi: 10.2165/00023210-200620040-00002.CNS Drugs. 2006.PMID:16599646Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical